Disclosed in the present invention are a CLY series compound, a preparation method therefor and the use thereof in the preparation of drugs. The CLY series compound is a compound with a structure of formula I, a
tautomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.
Animal model experiments show that the CLY series compound, in a chloasma mouse model, can obviously reduce the level oftyrosinase in the
skin and blood, reduce the expression of the
stem cell factor (SCF) and C-Kit
protein in the
skin, and inhibit the chromogenesis of chloasma, can obviously promote the healing of a wound on
skin and reduce the formation of
scars, in a
hair loss mouse model, can obviously promote the
hair growth and reduce damage to hair follicles, and in a rabbit ear
acne model, can obviously reduce the symptoms and reduce pore blockage and
acne formation. The CLY series compound can significantly prolong the survival time of acute GVHD mice, and can reduce clinical symptoms, exhibiting a
therapeutic effect on acute GVHD; in a
pulmonary fibrosis mouse model, same can obviously reduce the levels ofMMP-2 and MMP-9 in the
lung tissue, increase the levels of TIMP-1 and VEGF, and simultaneously increase the levels of SOD and CAT enzymes in
peripheral blood; and same can also improve the
arthritis symptoms ofrheumatoid
arthritis mice by means of reducing the level of IL-17 in
peripheral blood and increasing inflammatory indexes such as IL-10. The compound can be used alone or in ombination with other drugs, and provides a new
drug choice for the treatment of the above diseases.